Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 26, 1998

View Archived Issues

Laminin-related polypeptides from the University of Minnesota

Matritech receives SBIR grant for cancer test development

SS Pharm. describes new triazoles with oral activity

Squalene synthase inhibitors patented by Pfizer

Imidazoles for reversing MDR prepared at Ontogen

Dual 5-HT reuptake inhibitors/5-HT1A antagonists developed at Lilly

Virus-host cell fusion inhibitors under study at Lilly

Agents for schizophrenia without EPS disclosed by Warner-Lambert

New heterocyclic bradykinin antagonists from Fujisawa

Ortho reveals new fibrinogen receptor antagonists

Two NDAs up for review this week by Cardiovascular and Renal Drugs Advisory Committee

Neuroprotective effects of new PARS inhibitor

European alliance formed by Faulding and Asta Medica

Theratechnologies' novel cancer treatment granted additional patent protection

ProstaScint may predict response of prostate cancer patients to salvage radiotherapy

Clinical trial status of pain control implant updated by CytoTherapeutics/Astra

Expansion of Advanced Tissues Sciences/Smith & Nephew joint venture planned

Pfizer updates development pipeline

Nabi's Altastaph enters phase I/II

Additional data submitted to FDA to support Novastan NDA

Atherosclerosis program at Genome Therapeutics expanded

Adenosine metabolism inhibitor research at Cypros supported by grant

Randomized trial compares interferon alfa-2b + ribavirin to interferon alone for HCV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 27, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Sumitomo’s DSP-3456 exerts antidepressant-like effects
BioWorld Science
About one-third of patients with major depressive disorder (MDD) are treatment resistant. Ketamine is very effective in treatment-resistant depression, but it is...